|Bid||5.01 x 800|
|Ask||5.55 x 800|
|Day's Range||5.11 - 5.50|
|52 Week Range||0.52 - 8.48|
|Beta (3Y Monthly)||-0.21|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.25|
Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that Harel Gadot, Chief Executive Officer, President, and Chairman, is scheduled to present at the Ladenburg Thalmann Healthcare Conference on Tuesday, October 2, 2018 at 1:30 pm (ET) at the Sofitel Hotel in New York City. Microbot™, which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body.
Following the successful outcome of the initial study, Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced the commencement of a follow up pivotal study to evaluate the safety and efficacy of the Company’s Self-Cleaning Shunt (SCS™). The follow up study will be conducted by leading hydrocephalus experts at Washington University in St. Louis, MO and Wayne State University in Detroit, MI. The study will include a larger sample size compared to the initial study and the primary and secondary endpoints will seek to validate the safety and efficacy of the SCS that will be activated in both in-vitro (lab) and in-vivo (animal) models. The Company believes the follow up study will continue to support the safety and efficacy of its SCS product and plans to use the findings for its regulatory submissions in the US, Europe and other jurisdictions.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tiffany & Co. (NYSE: TIF ) stock was trading higher ...
LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company's latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company's Self-Cleaning Shunt (SCS). Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical.
Harel Gadot is the CEO of Microbot Medical Inc (NASDAQ:MBOT), which has recently grown to a market capitalization of US$37.62M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...
Harel Gadot took the helm as Microbot Medical Inc’s (NASDAQ:MBOT) CEO and grew market cap to USD$48.45M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...